Other team members include Bryan study McIver, MB, Ch.B., Ph.D., Norman Eberhardt, Ph.D.D. and Stefan Grebe, MD , all of Mayo Clinic. Translation of this research in a clinical setting is done in collaboration with Dr. Grebe. The study was funded by the Mayo Clinic, the Fraternal Order of Eagles, and the National Institutes of Health. The Career Development Award supported Dr. McIver Emslander.‘This is not an oncogene, as we all thought it was,’ says Dr. Reddi, referring to a gene with the potential to cause cancer. ‘We all knew what happened in cell culture, but we said: ‘This is not good enough’, so we asked: ‘What would he do in mice?’

Thyroid cancer is the sixth most common cancer worldwide, and 15 to 20 % of cases of follicular thyroid cancer is a type that is more aggressive. The results of Dr. Reddi could facilitate the diagnosis and treatment for thousands of patients.

Dr. Reddi discovery could have implications widely used in cancer research and endocrinology. It could help oncologists improve the diagnosis of certain types of thyroid cancer, while researchers leads to therapeutic pharmaceutical derived from a protein that is believed to fuel tumor growth.

Based on discussions with the doctors at the Mayo Clinic, Dr. Reddi said: ‘There are many complications of thyroid surgery, and markers for early detection can save thousands of unnecessary surgery each year. We have just started and turn for a quick translation from bench to bedside. ‘

Olympus proprietary technology, 3D visualization ScopeGuide allows the endoscopist to see the ring formations that occur in the management cycle faster and more efficient. It can also help the field of integration and management to optimize the scope, able to shorten the processing time and minimize patient discomfort, even during difficult colonoscopy.

A mutant gene, long thought to accelerate tumor growth in patients with thyroid gland that inhibits the spread of malignant cells, promising results for cancer treatment, a Mayo Clinic study has found. The results are presented by the researcher at the Mayo Clinic Honey Reddi, Ph.D., at the meeting of the Endocrine Society in Boston

The objectives of the research team in the future is to identify miRNA-like other markers that may identify a mild disease and avoid the need for immediate surgery and unnecessary.

The results of PAX8/PPAR translocation of genetic material between human chromosomes 2 and 3. Previous studies in vitro PAX8/PPAR protein is a rapid acceleration of cell growth, which has led researchers to PAX8/PPAR interpretation that functioned as an oncogene, a type of gene that promotes the spread of tumors, said Dr.

Reddi .